Last updated on April 2019

A Study to Evaluate the Efficacy Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Brief description of study

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.

Clinical Study Identifier: NCT03375203

Contact Investigators or Research Sites near you

Start Over

Sekino Hospital

Toshima-Ku, Japan

Shinjuku Research Park Clinic

Shinjuku-Ku, Japan

Suimin Sogo Care Clinic Yoyogi

Shibuya-Ku, Japan

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.